Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 mRNA vaccines: Platforms and current developments
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 200

Showing 1-25 of 200 citing articles:

Chemistry, structure and function of approved oligonucleotide therapeutics
Martin Egli, Muthiah Manoharan
Nucleic Acids Research (2023) Vol. 51, Iss. 6, pp. 2529-2573
Open Access | Times Cited: 398
RNA interference in the era of nucleic acid therapeutics
Vasant Jadhav, Akshay Vaishnaw, Kevin Fitzgerald, et al.
Nature Biotechnology (2024)
Closed Access | Times Cited: 74
Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification
Qisong Liu, Defeng Li, Xiaohua Pan, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 56
Circular RNA: A promising new star of vaccine
Jindong Xie, F. Ye, Xinpei Deng, et al.
Journal of Translational Internal Medicine (2023) Vol. 11, Iss. 4, pp. 372-381
Open Access | Times Cited: 45
Exosome for mRNA delivery: strategies and therapeutic applications
Zoya Iqbal, Khurrum Rehman, Ayesha Mahmood, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 25
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Norbert Pardi, Florian Krammer
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 23
Vaccine Strategies to Elicit Mucosal Immunity
Yufeng Song, Frances Mehl, Steven L. Zeichner
Vaccines (2024) Vol. 12, Iss. 2, pp. 191-191
Open Access | Times Cited: 22
mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
Vivek P. Chavda, Shailvi Soni, Lalitkumar K. Vora, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2150-2150
Open Access | Times Cited: 64
The Delivery of mRNA Vaccines for Therapeutics
Nitika Nitika, Wei Jiao, Ai‐Min Hui
Life (2022) Vol. 12, Iss. 8, pp. 1254-1254
Open Access | Times Cited: 54
Development of mRNA vaccines against respiratory syncytial virus (RSV)
Xirui Qiu, Siyan Xu, Yang Lu, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 68, pp. 37-53
Closed Access | Times Cited: 45
Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
Mena Hajiaghapour Asr, Fatemeh Dayani, Fatemeh Saedi Segherloo, et al.
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1127-1127
Open Access | Times Cited: 42
Unwinding circular RNA’s role in inflammatory pulmonary diseases
Asif Ahmad Bhat, Gaurav Gupta, Ahsas Goyal, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 5, pp. 2567-2588
Closed Access | Times Cited: 40
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 36
Functions of Circular RNA in Human Diseases and Illnesses
Alison Gu, Dabbu Kumar Jaijyan, Shaomin Yang, et al.
Non-Coding RNA (2023) Vol. 9, Iss. 4, pp. 38-38
Open Access | Times Cited: 31
Nucleic acid drugs: recent progress and future perspectives
Xiaoyi Sun, Sarra Setrerrahmane, Chencheng Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study
Monika Raethke, Florence van Hunsel, Nicoletta Luxi, et al.
Vaccine (2024) Vol. 42, Iss. 9, pp. 2357-2369
Open Access | Times Cited: 11
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 10
mRNA vaccines: a new era in vaccine development
Shubhra Chandra, Jennifer C Wilson, David M. Good, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 10, pp. 1543-1564
Open Access | Times Cited: 9
Globally approved vaccines for COVID-19: a systematic review
Bárbara Magalhães, Jéssica Medeiros Minasi, Rubens Cáurio Lobato, et al.
Brazilian Journal of Microbiology (2025)
Closed Access | Times Cited: 1
mRNA Technology in Modern Medicine: Review and Future Prospects
Heslley Machado Silva
Deleted Journal (2025) Vol. 2, pp. 1-1
Closed Access | Times Cited: 1
Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines
Li Zhang, Brandon Yi Loong Seow, K Ba, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 108-124
Closed Access | Times Cited: 1
A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants
Danyi Ao, Dandan Peng, Cai He, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access | Times Cited: 1
Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects
Zijing Wei, Shuai Zhang, Xingya Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy
Dariush Haghmorad, Majid Eslami, Niloufar Orooji, et al.
Frontiers in Bioengineering and Biotechnology (2025) Vol. 13
Open Access | Times Cited: 1
Modified-Release Pulmonary Delivery Systems for Labile Bioactives: Design, Development, and Applications
Shivani Nana, Mershen Govender, Yahya E. Choonara
Pharmaceutics (2025) Vol. 17, Iss. 4, pp. 470-470
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top